Search

Your search keyword '"Menna, Pierantonio"' showing total 211 results
Start Over Author "Menna, Pierantonio"
211 results on '"Menna, Pierantonio"'

2. Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)

Author

Maschmeyer, Georg, Bullinger, Lars, Garcia-Vidal, Carolina, Herbrecht, Raoul, Maertens, Johan, Menna, Pierantonio, Pagano, Livio, Thiebaut-Bertrand, Anne, and Calandra, Thierry

Published
2022
Full Text
View/download PDF

5. Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)

Author

Maschmeyer, Georg, Bullinger, Lars, Garcia-Vidal, Carolina, Herbrecht, Raoul, Maertens, Johan, Menna, Pierantonio, Pagano, Livio, Thiebaut-Bertrand, Anne, and Calandra, Thierry

Published
2022
Full Text
View/download PDF

6. P487: MIDOSTAURIN PLASMA EXPOSURE IN PATIENTS WITH FLT3-MUT ACUTE MYELOID LEUKEMIA UNDERGOING POSACONAZOLE PROPHYLAXIS DURING INDUCTION TREATMENT: A PROSPECTIVE MULTICENTRE STUDY FROM THE SEIFEM GROUP

Author

Marchesi, Francesco, primary, Menna, Pierantonio, additional, Cattaneo, Chiara, additional, Candoni, Anna, additional, Delia, Mario, additional, Nadali, Gianpaolo, additional, Pasciolla, Crescenza, additional, Perrone, Salvatore, additional, Verga, Luisa, additional, Armiento, Daniele, additional, Ilaria DEL Principe, Maria, additional, Stefano Fracchiolla, Nicola, additional, Salvatorelli, Emanuela, additional, Lupisella, S, additional, Terrenato, Irene, additional, Busca, Alessandro, additional, and Pagano, Livio, additional

Published
2023
Full Text
View/download PDF

7. Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study

Author

Menna, Pierantonio, primary, Marchesi, Francesco, additional, Cattaneo, Chiara, additional, Candoni, Anna, additional, Delia, Mario, additional, Nadali, Gianpaolo, additional, Vatteroni, Alessandra, additional, Pasciolla, Crescenza, additional, Perrone, Salvatore, additional, Verga, Luisa, additional, Armiento, Daniele, additional, Del Principe, Maria Ilaria, additional, Fracchiolla, Nicola S., additional, Salvatorelli, Emanuela, additional, Lupisella, Santina, additional, Terrenato, Irene, additional, Busca, Alessandro, additional, Minotti, Giorgio, additional, and Pagano, Livio, additional

Published
2023
Full Text
View/download PDF

8. N°94 – Reduction of EEG connectivity induced by cenobamate correlates with clinical and cognitive outcomes

Author

Assenza, Giovanni, primary, Ricci, Lorenzo, additional, Vico, Carlo, additional, Narducci, Flavia, additional, Boscarino, Marilisa, additional, Sancetta, Biagio, additional, Lanzone, Jacopo, additional, Menna, Pierantonio, additional, Fernandes, Mariana, additional, Lupo, Clementina, additional, Tufo, Tommaso, additional, Liguori, Claudio, additional, Nicola Mercuri, Biagio, additional, di Lazzaro, Vincenzo, additional, and Tombini, Mario, additional

Published
2023
Full Text
View/download PDF

9. Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry.

Author

Molteni, Linda, Charlier, Bruno, Coglianese, Albino, Izzo, Viviana, Assenza, Giovanni, Menna, Pierantonio, de Grazia, Ugo, and D'Urso, Annachiara

Subjects
LIQUID chromatography-mass spectrometry, ANTICONVULSANTS, SEIZURES (Medicine), DRUG monitoring, MATRIX effect, PEOPLE with epilepsy, MASS transfer coefficients
Abstract

Cenobamate (CNB) is a new anti-seizure medication (ASM) recently introduced in clinical practice after approval by the FDA and EMA for the add-on treatment of focal onset seizures in adult patients. Although its mechanism of action has not been fully understood, CNB showed promising clinical efficacy in patients treated with concomitant ASMs. The accessibility of CNB could pave a way for the treatment of refractory or drug-resistant epilepsies, which still affect at least one-third of the patients under pharmacological treatment. In this context, therapeutic drug monitoring (TDM) offers a massive opportunity for better management of epileptic patients, especially those undergoing combined therapy. Here, we describe the first fully validated ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC–MS/MS) method for the quantification of CNB and concomitant ASMs in human plasma, with samples extracted either manually or by means of a liquid handler. Our method was validated according to the most recent ICH International Guideline M10 for Bioanalytical Method Validation and Study Sample Analysis. The method proved to be selective for CNB and displayed a linear range from 0.8 to 80 mg/L; no matrix effect was found (98.2 ± 4.1%), while intra-day and inter-day accuracy and precision were within the acceptance range. Also, CNB short- and long-term stability in plasma under different conditions was assessed. Leftover human plasma samples were employed as study samples for method validation. Our method proved to be highly sensitive and selective to quantify CNB and concomitant ASMs in human plasma; therefore, this method can be employed for a routinely TDM-based approach to support physicians in the management of an epileptic patient. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Anthracyclins

Author

Minotti, Giorgio, Salvatorelli, Emanuela, Menna, Pierantonio, Offermanns, Stefan, editor, and Rosenthal, Walter, editor

Published
2008
Full Text
View/download PDF

18. Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death.

Author

Boriani, Giuseppe, Menna, Pierantonio, Morgagni, Riccardo, Minotti, Giorgio, and Vitolo, Marco

Subjects
*BRUTON tyrosine kinase, *TACHYARRHYTHMIAS, *CARDIAC arrest, *VENTRICULAR fibrillation, *CHRONIC lymphocytic leukemia, *ATRIAL fibrillation, *FLUDARABINE, *ALEMTUZUMAB
Abstract

Background: The natural history of chronic lymphocytic leukemia (CLL) was dramatically improved by the introduction of ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. In this review, we aimed to summarize and critically evaluate the association between first- and second-generation BTK inhibitors and the risk of atrial fibrillation (AF) and ventricular arrhythmias (VA). Summary: Since the first clinical experience, the development of AF was observed as the result of off-target effects that likely combined with patient's predisposing risk factors and concomitant cardiac morbidities. More recently, both ibrutinib dose reduction and arrhythmia management allowed long-term treatment, with positive effects on progression-free survival and reduced all-cause mortality as well. Second-generation BTK inhibitors, acalabrutinib, and zanubrutinib have been tested and validated in CLL. A lower occurrence of AF as compared with ibrutinib has been found, although AF has always been a secondary endpoint of all studies that probed these agents. Key Messages: For this reason, caution should be exercised before concluding that second-generation BTK inhibitors are safer than ibrutinib. Recent data on the effectiveness of ibrutinib over a follow-up of 8 years show a remarkable benefit on all-cause mortality, which is of great value also for interpreting the clinical impact of the few cases of VA and sudden cardiac death (SCD) reported for ibrutinib, independently of QT lengthening. Since a risk of VA and SCD has been recently reported also during treatment with second-generation BTK inhibitors, it appears that this risk, usually reaching its maximum size effect at long-term follow-up, likely denotes a class effect of BTK inhibitors. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Indicazioni per l’armonizzazione degli intervalli di riferimento nel monitoraggio terapeutico di farmaci antiepilettici.

Author

de Grazia, Ugo, Menna, Pierantonio, Cantù, Marco, Baldelli, Sara, Goffredo, Bianca Maria, and Deleo, Francesco

Abstract

Therapeutic monitoring (TDM) of antiepileptic drugs (AEDs), or antiseizure medicines (ASMs) represents a pragmatic approach to the management of patients with epilepsy to assess either compliance, efficacy and toxicity. Dose adjustments based on drug concentrations detected in biological fluids allow physicians to optimize and personalize the pharmacologic regimens for the single patient. TDM of AEDs has become increasingly popular since the 1970s because it is difficult to identify the optimal drug dose for each patient and because AEDs concentrations correlate better than dose with clinical effects. This document aims to suggest reference intervals to harmonize the pharmacokinetic activity among Italian Laboratories in the monitoring of AEDs plasma exposures according to recent international literature and guidelines. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study

Author

Cattaneo, Chiara, primary, Marchesi, Francesco, additional, Terrenato, Irene, additional, Bonuomo, Valentina, additional, Fracchiolla, Nicola Stefano, additional, Delia, Mario, additional, Criscuolo, Marianna, additional, Candoni, Anna, additional, Prezioso, Lucia, additional, Facchinelli, Davide, additional, Pasciolla, Crescenza, additional, Del Principe, Maria Ilaria, additional, Dargenio, Michelina, additional, Buquicchio, Caterina, additional, Mitra, Maria Enza, additional, Farina, Francesca, additional, Borlenghi, Erika, additional, Nadali, Gianpaolo, additional, Gagliardi, Vito Pier, additional, Fianchi, Luana, additional, Sciumè, Mariarita, additional, Menna, Pierantonio, additional, Busca, Alessandro, additional, Rossi, Giuseppe, additional, and Pagano, Livio, additional

Published
2022
Full Text
View/download PDF

24. Safety and tolerability of a novel oral nutritional supplement in healthy volunteers

Author

Bonelli, Annalisa, primary, Menna, Pierantonio, additional, Minotti, Giorgio, additional, Angeletti, Silvia, additional, Comandini, Alessandro, additional, Picollo, Rossella, additional, Quarchioni, Elisa, additional, Russo, Vincenzo, additional, Salvatori, Enrica, additional, Ferravante, Francesca, additional, Emerenziani, Sara, additional, Cicala, Michele, additional, and Muscaritoli, Maurizio, additional

Published
2021
Full Text
View/download PDF

29. In ®Entresto we trust

Author

Camilli, Massimiliano, primary, Del Buono, Marco Giuseppe, additional, Menna, Pierantonio, additional, and Minotti, Giorgio, additional

Published
2020
Full Text
View/download PDF

37. Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial

Author

Minotti, Giorgio, primary, Menna, Pierantonio, additional, Calabrese, Vito, additional, Greco, Carlo, additional, Armento, Grazia, additional, Annibali, Ombretta, additional, Marchesi, Francesco, additional, Salvatorelli, Emanuela, additional, and Reggiardo, Giorgio, additional

Published
2019
Full Text
View/download PDF

38. The Endogenous Lusitropic and Chronotropic Agent, B-Type Natriuretic Peptide, Limits Cardiac Troponin Release in Cancer Patients with an Early Impairment of Myocardial Relaxation Induced by Anthracyclines

Author

Menna, Pierantonio, primary, Salvatorelli, Emanuela, additional, Armento, Grazia, additional, Annibali, Ombretta, additional, Greco, Carlo, additional, Marchesi, Francesco, additional, Calabrese, Vito, additional, Reggiardo, Giorgio, additional, and Minotti, Giorgio, additional

Published
2018
Full Text
View/download PDF

39. Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy

Author

Menna, Pierantonio, primary, Calabrese, Vito, additional, Armento, Grazia, additional, Annibali, Ombretta, additional, Greco, Carlo, additional, Salvatorelli, Emanuela, additional, Marchesi, Francesco, additional, Reggiardo, Giorgio, additional, and Minotti, Giorgio, additional

Published
2018
Full Text
View/download PDF

48. Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study.

Author

Calabrese, Vito, Menna, Pierantonio, Annibali, Ombretta, Armento, Grazia, Carpino, Armando, Cerchiara, Elisabetta, Greco, Carlo, Marchesi, Francesco, Spallarossa, Paolo, Toglia, Giuseppe, Reggiardo, Giorgio, and Minotti, Giorgio

Subjects
*BIOLOGICAL tags, *ECHOCARDIOGRAPHY, *CARDIOTOXICITY, *CANCER chemotherapy, *CANCER
Abstract

Asymptomatic diastolic dysfunction (DD) with preserved left ventricular ejection fraction (LVEF) is suspected to precede late cardiac events in cancer survivors treated by chemotherapy. We conducted the first multicenter study of early DD induced by chemotherapy. Patients who were candidates for standard dose chemotherapy were screened for the absence of cardiovascular risk factors, LVEF ≥50%, normal-for-age diastolic function at echocardiography (E/A ratio, E wave deceleration time; DT), normal levels of potential DD biomarkers like Nt-proBNP (≤125 pg/mL), and cardiac troponin I (cTnI, ≤0.05 ng/mL). Mitral Doppler (E/E’) was left at the investigator’s discretion. Chemotherapy-induced DD with preserved LVEF was diagnosed for patients showing LVEF ≥50% and any of the following: Nt-proBNP > 125 pg/mL, cTnI > 0.05 ng/mL, and out-of-range E/A and DT. Eighty patients (68 males, 12 females, median age 49 years) were evaluated at 1 week after chemotherapy (T1). Thirty-three protocol-defined diastolic events were observed (15 Nt-proBNP > 125 pg/mL, 14 grade I DD by E/A and DT, 4 cTnI > 0.05 ng/mL). The events occurred in 29 asymptomatic patients with LVEF ≥50% (36% incidence of DD with preserved LVEF). Interactions occurred between biomarkers and grade I DD. E/E’ abnormalities were not observed. Both anthracycline-based and nonanthracycline regimens induced DD. These findings show that biomarkers and echocardiography intercept early DD in otherwise asymptomatic low-risk cancer patients treated by standard dose chemotherapy. These findings therefore call for the adequate cardiac management of cancer patients. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

49. Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy.

Author

Menna, Pierantonio, Salvatorelli, Emanuela, Mattei, Alessia, Cappiello, Dario, Minotti, Giorgio, and Carassiti, Massimiliano

Subjects
*DRUG resistance in bacteria, *ANTIBACTERIAL agents, *PHARMACOKINETICS, *METHANESULFONATES, *ORGANOSULFUR compounds
Abstract

Colistin is a last resort antibiotic to treat multidrug-resistant Gram-negative bacteria infections. Colistin is administered intravenously in the form of its inactive prodrug colistin methanesulfonate (CMS). For patients with acute kidney impairment and continuous renal replacement therapy high extracorporeal clearance may cause a substantial removal of active colistin from the bloodstream, eventually decreasing its antibacterial efficacy. Currently recommended doses of CMS may therefore be inadequate for these patients. We report on the potential value of a modified regimen that adopts a loading dose of CMS (bolus of 9 MU vs. conventional 3 MU every 8 h), followed by maintenance (3 MU every 8 h). Preliminary pharmacokinetic evidence for the feasibility and efficacy of this regimen is described for 2 patients. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results